Amgen gets action date on Xgeva cancer use; Afexa tells investors to hold off on Paladin bid;

@FiercePharma: On top of 280 Irish jobs saved in Pfizer plant buyout. RT @lisamjarvis: Amgen to add Dublin plant, creating 100 jobs. Report | Follow @FiercePharma

> Amgen ($AMGN) said the FDA has targeted April 26 for its decision on whether to expand use of Xgeva to reduce the risk of bone metastases in men with castrate-resistant prostate cancer. Amgen release

> Afexa Life Sciences is urging shareholders to hang tight on a hostile bid from Paladin Labs, saying the $57.3 million offer undervalues the company. News

> Eli Lilly ($LLY) boosted its second-quarter spending on lobbying in Washington, to $1.9 million from $1.6 million during the same period last year. Report

> Valeant Pharmaceuticals ($VRX) wrapped up its $441 million purchase of AB Sanitas, the Lithuanian specialty pharma. Item

> Private equity firm Advent International bought a majority stake in the Argentine specialty drugmaker Laboratorio LKM and plans to invest $12 million in expanding the company. Article

> Vertex Pharmaceuticals ($VRTX) got the regulatory nod in Canada for its new hepatitis C drug Incivek. Vertex release

> AstraZeneca ($AZN) said its new clot-prevention drug Brilinta has hit pharmacy shelves in the U.S. AstraZeneca release

> Norgine licensed its bowel drug Moviprep to Nycomed for sale in 11 eastern markets, including Russia, Azerbaijan and Ukraine. Story 

> Takeda Pharmaceutical said it will receive a Japanese government subsidy of ¥23.9 billion ($37 million) to develop a new flu vaccine. Piece

Biotech News

@FierceBiotech: A group of researchers hope to grow spare heart parts from embryonic stem cells within 5 years. Report | Follow @FierceBiotech

@JohnCFierce: Fresh off the Zelboraf win, Roche CEO Schwan does the visionary thing on pharma's bright future. Story | Follow @JohnCFierce

@RyanMFierce: A computerized blueprint for starving cancer cells: Group created the first genome-scale model of cancer cell. Item | Follow @RyanMFierce

@MaureenFierce: FDA pins approval on Seattle Genetics' cancer drug Adcetris. Article | Follow @MaureenFierce

> BMS, Pfizer ready key data on closely-watched apixaban. Details

> Catalent snaps up Aptuit's trial supplies ops for $410M. Story

> Roche CEO Schwan spotlights Roche's top three blockbuster hopefuls. More

> FDA pins approval on Seattle Genetics' cancer drug Adcetris. News

> New GSK spinout grabs £10M, top researchers and drugs for hearing loss. Report

> Roche abstract paints promising picture of a potential mega-blockbuster. Article

Biotech IT News

> Medtronic works to thwart device hackers. Story

> Perfect algorithm proves elusive for DREAM teams. More

> A computerizing blueprint for starving cancer. Article

> Computational method rapidly discovers new uses for approved drugs. Details

> Vital models emerging to enable personalized cancer care. Report

> Deloitte grabs drug regulatory tech in new buyout. News

Medical Device News

> Wright Medical sees another top exec go. Item

> Shareholders thwart Alere's takeover attempt of Axis-Shield. Article

> TheraSolve closes first financing round. Report

> Sources: Kinetic receives higher buyout offer. Details

> Report: Medrad to buy Pathway for $125M. News

> Intersect ENT CEO discusses Propel implant. More

> Tangent taps Accuri, HandyLab vet as CEO. Story

And Finally... The incidence of ADHD has risen by 30% over a decade as increased awareness has boosted diagnosis. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.